Simulations Plus, Inc. (NASDAQ:SLP) Stock Position Raised by Royce & Associates LP

Royce & Associates LP lifted its position in Simulations Plus, Inc. (NASDAQ:SLP) by 28.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 237,416 shares of the technology company’s stock after acquiring an additional 53,092 shares during the quarter. Royce & Associates LP’s holdings in Simulations Plus were worth $7,602,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in SLP. Allspring Global Investments Holdings LLC purchased a new stake in Simulations Plus in the 1st quarter worth approximately $70,000. BNP Paribas Financial Markets lifted its position in Simulations Plus by 9.1% in the 1st quarter. BNP Paribas Financial Markets now owns 14,143 shares of the technology company’s stock worth $582,000 after buying an additional 1,174 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in Simulations Plus in the 1st quarter worth approximately $208,000. Vanguard Group Inc. lifted its position in Simulations Plus by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 1,135,105 shares of the technology company’s stock worth $46,710,000 after buying an additional 12,636 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Simulations Plus in the 1st quarter worth approximately $57,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total transaction of $625,200.00. Following the completion of the transaction, the director now directly owns 3,481,592 shares of the company’s stock, valued at $108,834,565.92. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 60,750 shares of company stock valued at $1,905,655. Company insiders own 20.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SLP. Stephens began coverage on shares of Simulations Plus in a report on Friday. They set an “overweight” rating and a $39.00 price target on the stock. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. KeyCorp began coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price on the stock. Finally, BTIG Research lowered their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Simulations Plus Price Performance

NASDAQ SLP opened at $28.77 on Monday. The firm has a market capitalization of $577.41 million, a price-to-earnings ratio of 58.72 and a beta of 0.71. The company’s fifty day moving average is $31.19 and its two-hundred day moving average is $38.88. Simulations Plus, Inc. has a 52-week low of $27.22 and a 52-week high of $51.22.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business’s quarterly revenue was up 19.9% on a year-over-year basis. During the same period last year, the business posted $0.18 EPS. As a group, sell-side analysts expect that Simulations Plus, Inc. will post 1.12 earnings per share for the current fiscal year.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.